论文部分内容阅读
目的探讨胰激肽原酶联合阿魏酸钠治疗早期糖尿病肾病的疗效。方法将54例早期糖尿病肾病患者在严格控制血压、血脂、血糖基础上,随机分成对照组和治疗组,分别用胰激肽原酶、阿魏酸钠及二者联应合用三组。结果各组治疗前后对尿微量白蛋白排泄率(UAE)均有显著减少(P<0.05),但是联合组优于单药组(P<0.01)。结论胰激肽原酶与阿魏酸钠联合治疗早期糖尿病肾病优于单药组,存在协同作用,延缓了糖尿病肾病的发展。
Objective To investigate the efficacy of pancreatic kallikrein combined with sodium ferulate in the treatment of early diabetic nephropathy. Methods 54 patients with early diabetic nephropathy were randomly divided into control group and treatment group on the basis of strict control of blood pressure, blood lipids and blood glucose. Three groups of patients were treated with pancreatic kallikrein, sodium ferulate and their combination respectively. Results Before and after treatment, the urinary albumin excretion rate (UAE) was significantly decreased (P <0.05), but the combined group was better than the single drug group (P <0.01). Conclusions The combination of pancreatic kallikrein and sodium ferulate is better than single drug group in the treatment of early diabetic nephropathy, which has a synergistic effect and delays the development of diabetic nephropathy.